Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 6;12(11):e029282.
doi: 10.1161/JAHA.122.029282. Online ahead of print.

Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity

Erin D Michos  1 , Francisco Lopez-Jimenez  2 , Martha Gulati  3
Affiliations
Review

Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity

Erin D Michos et al. J Am Heart Assoc. .

Abstract

Obesity remains a major public health problem, affecting almost half of adults in the United States. Increased risk of cardiovascular disease (CVD) and CVD mortality are major obesity-related complications, and management guidelines now recommend weight loss as a key strategy for the primary prevention of CVD in patients with overweight or obesity. The recently demonstrated efficacy of some pharmacologic therapies for chronic weight management may encourage health care professionals to recognize obesity as a treatable serious chronic disease and motivate patients to re-engage with weight loss when previous attempts have been ineffective or unsustainable. This review article summarizes the benefits and challenges associated with lifestyle changes, bariatric surgery, and historical pharmacologic interventions in the treatment of obesity, and focuses on the current evidence for the efficacy and safety of the newer glucagon-like peptide-1 receptor agonist medications in the management of obesity and potential reduction of CVD risk. We conclude that the available evidence demonstrates glucagon-like peptide-1 receptor agonists should be strongly considered in clinical practice for the treatment of obesity and reduction of CVD risk in people with type 2 diabetes. If ongoing research proves glucagon-like peptide-1 receptor agonists to be effective in reducing the risk of CVD onset in patients with obesity, irrespective of type 2 diabetes status, it will herald a new treatment paradigm in this setting, and now is the time for health care professionals to better recognize the benefits of these agents.

Keywords: GLP‐1 RA; obesity; overweight; weight loss.

PubMed Disclaimer

Figures

Figure 1
Figure 1. The role of GLP‐1 RAs in achieving weight loss and improving cardiovascular outcomes in people with overweight and obesity., , , , , , , , , , , , , , , , , , , , , , , , , , , ,
BP indicates blood pressure; BMI, body mass index; CV, cardiovascular; CVD, cardiovascular disease; FDA, Food and Drug Administration; GI, gastrointestinal; GLP‐1 RA, glucagon‐like peptide‐1 receptor agonist; HCP, health care professional; MACE, major adverse cardiovascular event; s.c., subcutaneous; and T2D, type 2 diabetes.
See this image and copyright information in PMC

References

    1. Fryar CD, Carroll MD, Afful J. Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960–1962 through 2017–2018. NCHS Health E‐Stats. Centers for Disease Control and Prevention. 2020. Accessed April 1, 2023. www.cdc.gov/nchs/data/hestat/obesity‐adult‐17‐18/obesity‐adult.htm
    1. Stierman B, Afful J, Carroll MD, Chen TC, Davy O, Fink S, Fryar CD, Gu Q, Hales CM, Hughes JP, et al. National Health and Nutrition Examination Survey 2017–March 2020 prepandemic data files—development of files and prevalence estimates for selected health outcomes [published correction appears in NHSR No. 158]. National Health Statistics Reports. Centers for Disease Control and Prevention. 2021. Accessed April 1, 2023. https://www.cdc.gov/nchs/data/nhsr/nhsr158‐508.pdf.
    1. Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, Long MW, Gortmaker SL. Projected U.S. state‐level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381:2440–2450. doi: 10.1056/NEJMsa1909301 - DOI - PubMed
    1. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co‐morbidities related to obesity and overweight: a systematic review and meta‐analysis. BMC Public Health. 2009;9:88. doi: 10.1186/1471-2458-9-88 - DOI - PMC - PubMed
    1. Lopez‐Jimenez F, Almahmeed W, Bays H, Cuevas A, Di Angelantonio E, le Roux CW, Sattar N, Sun MC, Wittert G, Pinto FJ, et al. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. Eur J Prev Cardiol. 2022;29:2218–2237. doi: 10.1093/eurjpc/zwac187 - DOI - PubMed

LinkOut - more resources